Watch XBIT. Know when insiders buy.
One email the day a filing lands. Free.
XBIT
XBiotech Inc.
2.19
−0.01 −0.45%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · shorts 43
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $66.8MP/E —DIV YIELD —FCF YIELD -61.17%REV TTM —NET INCOME −$45.1MNET CASH —52W 2.12 – 2.94SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.1M | −$6.7M | — | -0.22 | −$4.5M | $0 | −$4.5M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$6.3M | −$5.5M | — | -0.18 | −$9M | $0 | −$9M | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$29.8M | −$26.9M | — | -0.88 | −$23M | $34K | −$23M | Mar 13 |
| Q3 2025 · Sep 30 | — | — | — | −$6M | −$6M | — | -0.20 | −$4.3M | $110K | −$4.4M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$6.3M | −$1.8M | — | -0.06 | −$6M | $51K | −$6M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$13.6M | −$10.9M | — | -0.36 | −$6.7M | $94K | −$6.8M | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.7M | −$10.5M | — | -0.34 | −$6.5M | $84K | −$6.6M | Mar 13 |
| Q3 2024 · Sep 30 | — | — | — | −$7.9M | −$5M | — | -0.16 | −$5.8M | $338K | −$6.2M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$15M | −$13M | — | -0.43 | −$11.4M | $627K | −$12M | Aug 13 |
| Q1 2024 · Mar 31 | — | — | — | −$10.9M | −$10M | — | -0.33 | −$7.2M | $255K | −$7.5M | May 14 |
| Q4 2023 · Dec 31 | — | — | — | −$8.6M | −$4.6M | — | -0.15 | −$3.4M | $115K | −$3.5M | Mar 18 |
| Q3 2023 · Sep 30 | — | — | — | −$8.5M | −$7.4M | — | -0.24 | −$1.5M | $33K | −$1.5M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$55.7M | −$45.5M | — | -1.49 | −$39.9M | $289K | −$40.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$42.5M | −$38.5M | — | -1.26 | −$31M | $1.3M | −$32.3M | $0 | — |
| FY2023 · to Dec 31 | — | — | −$37.5M | −$24.6M | — | -0.81 | −$18.7M | $362K | −$19.1M | $14K | — |
| FY2022 · to Dec 31 | — | — | −$34.5M | −$32.9M | — | -1.08 | −$14.8M | $585K | −$15.4M | $0 | $0 |
| FY2021 · to Dec 31 | — | — | −$25.1M | −$17.4M | — | -0.58 | $69.4M | $3.5M | $65.9M | — | $75M |
| FY2020 · to Dec 31 | — | — | −$18.3M | −$11.2M | — | -0.36 | −$65.1M | $3.7M | −$68.9M | — | $0 |
Every number comes from XBiotech Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.